Targeting CD30 in anaplastic large cell lymphoma.

about

Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma.Emerging antibody-drug conjugates for treating lymphoid malignancies.

P2860

Q37228493-4F21BD52-5E28-4FB8-9C04-095D78980DBF Q38632313-3C07FD9D-C2EA-4E04-85B1-AD5BDAD2572B

P2860

Targeting CD30 in anaplastic large cell lymphoma.

Item

http://www.wikidata.org/entity/Q38052082

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Targeting CD30 in anaplastic large cell lymphoma.

@en

type

Item

label

Targeting CD30 in anaplastic large cell lymphoma.

@en

prefLabel

Targeting CD30 in anaplastic large cell lymphoma.

@en

P1476

Targeting CD30 in anaplastic large cell lymphoma.

@en

P2093

Barbara Pro

http://www.w3.org/2001/XMLSchema#string

Joseph Vadakara

http://www.w3.org/2001/XMLSchema#string

P2860

Characteristic ribonucleolytic activity of human angiogenin

Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

P2888

s11899-012-0137-y

P304

285-291

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-012-0137-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Barbara Pro

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1041113117

http://www.w3.org/2001/XMLSchema#string

P698

23065407

http://www.w3.org/2001/XMLSchema#string

Targeting CD30 in anaplastic large cell lymphoma.

about

P2860

P2860

Targeting CD30 in anaplastic large cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698